JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033. Click here to read why JNJ is a Hold.

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Stelara, introduced in 2009, has been J&J’s top-selling drug since 2019, with sales reaching more than $10 billion in 2024. Its patents began to expire in 2023, opening the door to cheaper ...

Navitus will remove Stelara from formulary on July 1, 2025. Stelara, the brand name of the drug ustekinumab, is a popular treatment for plaque psoriasis, psoriatic arthritis, ulcerative colitis ...

Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA ...

The issue isn’t that Samsung Bioepis is selling its own Stelara biosimilar, according to J&J. Rather, the New Jersey drug giant is taking issue with Samsung Bioepis' move to sublicense "a second ...

FYB202/Otulfi ® (ustekinumab-aauz), a biosimilar to Stelara®, launched in the United States and the European Union FYB202/Otulfi ® is now commercially available in both subcutaneous and intravenous ...

2025 /PRNewswire/ -- Celltrion today announced the U.S. launch of STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab), following approval by the U.S. Food and Drug ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

Steqeyma, a biosimilar of Johnson & Johnson's blockbuster drug Stelara, received full-label approval from the US Food and Drug Administration last December for plaque psoriasis, psoriatic ...